The amplification of the HER2/neu gene results in Her2 overexpression, which occurs in approximately 20%-30% of ovarian and breast cancers and is associated with tumorigenesis, metastasis and a poor prognosis [18, 19]. Here, ERBB2 is linked to breast cancer.